Mucinous epidermoid carcinoma of the lung with ALK mutation: Case report and literature review
Lijiao Yang,Yanyan Ren,Xing Yin
DOI: https://doi.org/10.1097/md.0000000000038301
IF: 1.6
2024-06-01
Medicine
Abstract:Mucoepidermoid carcinoma (MEC) is an invasive malignant tumor commonly found in the salivary or lacrimal glands, whereas pulmonary mucoepidermoid carcinoma (PMEC) is rare. It is usually thought to originate from the ductal epithelial cells of the tracheal and bronchial submucosal glands, and its incidence accounts for 0.2% of primary lung tumors. [ 1 , 2 ] PMEC has atypical clinical features, complex pathologic and histologic components, and difficulty in preoperative diagnosis, and its traditional treatment is single, mainly surgical treatment, and the effect of adjuvant radiotherapy is still unsatisfactory. [ 3 ] Currently, the research progress of molecular targeted therapy is in full swing, and immunotherapy has opened a new chapter in human tumor treatment, but there is less experience in targeted therapy and immunotherapy for PMEC. Due to the low incidence of PMEC, there is less literature at home and abroad, and most of them are case reports, so there is a lack of summary of its clinical manifestations, pathologic features as well as histologic features, imaging features, clinical diagnosis and treatment, and prognosis. By reviewing the relevant literature on targeted therapy for PMEC, it is hypothesized that targeted therapy may be a new breakthrough in the treatment of PMEC. In this paper, we report a case of PMEC-based primary lung cancer combined with ALK mutation, and discuss the key issues of clinical diagnosis and treatment in the light of relevant literature review.
medicine, general & internal